로딩 중…
지수 로딩 중…
Biohaven Ltd.
BHVN· NYSE· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$13.61-2.05%
2026-09-18
Financials
Valuation Metrics
Biohaven Ltd.'s Market Cap is $2.05B. At end of 2025 it was $1.36B. Ranked #1994 of 3,121 in US market (top 64%), #1238 of 1,658 on NYSE (top 75%), #135 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.05B | US#1,994/3,121 Sec#135/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-587M | US—/3,121 Sec—/266 |
| Total Assets | $371M | US#2,867/3,121 Sec#195/266 |
| Net Assets | $12M | US#2,909/3,121 Sec#240/266 |
| Employees | 274 | US#2,436/3,121 Sec#115/266 |
| Value | ||
| P/B | 167.60x | US#2,914/3,121 Sec#239/266 |
| FCF Yield | -24.99% | US—/3,121 Sec—/266 |
| Financial Health | ||
| Debt Ratio | 2933.37% | US#2,886/3,121 Sec#238/266 |
| Total Debt | $297M | US#2,103/3,121 Sec#78/266 |
| FCF | $-512M | US#2,913/3,121 Sec#255/266 |
| Cash | $238M | US#1,603/3,121 Sec#96/266 |
| Current Ratio | 4.73x | US#509/3,121 Sec#153/266 |
| Performance | ||
| 1Y Return | -12.34% | US#1,984/3,121 Sec#192/266 |
| 1M Return | -3.78% | US#690/3,121 Sec#69/266 |
| From 52W High | -26.74% | US#1,798/3,121 Sec#138/266 |
| 1Y MDD | -56.99% | US#2,708/3,121 Sec#204/266 |
| Trading | ||
| Volume | 4,634,863 shares | US#314/3,121 Sec#25/266 |
| Trading Value | $64M | US#1,027/3,121 Sec#72/266 |
| Per Share | ||
| EPS | $-3.90 | US—/3,121 Sec—/266 |
| BPS | $0.08 | US#2,804/3,121 Sec#236/266 |
Company Info
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.